Skip to main content
. 2019 Jun 4;9(6):e024747. doi: 10.1136/bmjopen-2018-024747

Table 1.

Descriptive statistics for participants in four evidence-based drug classes (ATC code)

Medication Group
(no patients enrolled)
Antithrombotics (B01)
(n=13 684)
Lipid-lowering (C10)
(n=14 427)
Thyroid meds (H03)
(n=3484)
Respiratory inhalers (R03)
(n=5227)
No. patients at end of follow-up period Hospitalised
(n=2707)
Non-hospitalised
(n=6152)
Hospitalised
(n=2622)
Non-hospitalised
(n=6944)
Hospitalised
(n=586)
Non-hospitalised
(n=1641)
Hospitalised
(n=1067)
Non-hospitalised
(n=2110)
Mean(SD) Mean(SD) Mean(SD) Mean(SD) Mean(SD) Mean(SD) Mean(SD) Mean(SD)
Age (years) 78.38 (7.06) 75.32 (6.95) 77.05 (6.77) 73.78 (6.45) 78.34 (7.25) 74.59 (7.18) 76.88 (7.02) 74.29 (6.90)
No of consultations in enrolment period 18.28 (10.40) 14.80 (9.66) 17.50 (10.09) 13.71 (8.79) 18.76 (10.29) 14.81 (9.10) 19.64 (11.09) 16.07 (10.57)
No of repeat drug classes during enrolment period 8.04 (3.72) 7.01 (3.45) 7.77 (3.75) 6.44 (3.41) 8.59 (4.30) 6.67 (3.87) 9.26 (4.24) 7.99 (4.13)
RxRisk during enrolment period 5.07 (2.05) 4.55 (1.89) 4.99 (2.09) 4.26 (1.97) 5.37 (2.42) 4.36 (2.09) 4.79 (2.18) 4.29 (2.12)
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Female 1414 (52.23) 3176 (51.63) 1423 (54.27) 3957 (56.98) 468 (79.86) 1349 (82.21) 626 (58.67) 1276 (60.47)
Insurance type: GMS/DVC 2495 (92.17) 5495 (89.32) 2429 (92.64) 6194 (89.20) 537 (91.64) 1445 (88.06) 998 (93.53) 1898 (89.95)
Charlson index of 1 or more 1400 (51.72) 2638 (42.88) 1357 (51.75) 2736 (39.40) 290 (49.49) 543 (33.09) 690 (64.67) 1120 (53.08)
Patients experiencing one hospitalisation only during first follow-up period 2011 (74.29) 1958 (74.68) 457 (77.99) 761 (71.32)
Patients discontinued during 1st follow-up period 288 (10.64) 693 (11.26) 282 (10.76) 727 (10.47) 35 (5.97) 139 (8.47) 118 (11.06) 359 (17.01)

ATC, Anatomical Therapeutic Chemical classification system; DVC, doctor visit card; GMS, general medical services.